Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop
English
By (author): and Medicine Board on Health Sciences Policy Engineering Forum on Neuroscience and Nervous System Disorders Health and Medicine Division National Academies of Sciences
Psychiatric illnesses - such as major depressive disorder, anxiety disorder, substance use disorder, and posttraumatic stress disorder (PTSD) - are widely prevalent and represent a substantial health burden worldwide. Yet, conventional medications for mental illnesses often fail to provide relief to patients' disruptive and disabling symptoms. Existing and emerging evidence that psychedelics (e.g., LSD and psilocybin) and entactogens (e.g., MDMA) may be useful as tools to alleviate mental illness has sparked a renaissance of interest by investigators, clinicians, drug developers, and patient advocates in recent years. While promising data on therapeutic efficacy has energized research and development, resolving the mechanisms of action will be important for optimizing the efficacy and safety of these medicines. Further, evaluating the effect of psychedelics and entactogens on mood and behavior comes with unique challenges still in need of resolution. These include unresolved questions relating to blinding, placebo and nocebo effects, and the impact of psychosocial contexts.
In response to this renewed interest, the National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders convened a workshop on March 29-30, 2022. The workshop brought together a diverse group of stakeholders to explore the use of psychedelics and entactogens as treatments for psychiatric disorders. This Proceedings of a Workshop summarizes the presentations and discussions of the workshop.
Table of Contents- Front Matter
- 1 Introduction and Background
- 2 History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders
- 3 Mechanisms of Action and Key Research Gaps for Psychedelics and Entactogens
- 4 Advancing Clinical Development: Challenges and Opportunities
- 5 Anticipating Implementation to Guide Clinical Research and Development
- 6 Reflecting on the Road Ahead
- Appendix A: References
- Appendix B: Workshop Agenda